Johnson & Johnson Secures FDA Approval For First Rare Anemia Treatment
Johnson & Johnson secured FDA approval for IMAAVY, the first targeted therapy to treat warm autoimmune hemolytic anemia in adults and youth.
Johnson & Johnson got permission to sell a new medicine that treats a rare blood condition where the body hurts its own red blood cells. This is good news because it means the company has a new product to help patients and potentially make money from.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.